Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Buy
66
RMD Quote, Financials, Valuation and Earnings
Last price:
$254.38
Seasonality move
:
6.38%
Day range:
$250.84 - $255.47
52-week range:
$179.42 - $263.05
Dividend yield:
0.84%
P/E ratio:
28.47x
P/S ratio:
7.45x
P/B ratio:
6.71x
Volume:
964.4K
Avg. volume:
827.1K
1-year change:
23.66%
Market cap:
$37.2B
Revenue:
$4.7B
EPS (TTM):
$8.91
Analysts' Opinion
-
Consensus RatingResMed has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 6 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $264.49, ResMed has an estimated upside of 4.26% from its current price of $254.52.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $200.00 representing 100% downside risk from its current price of $254.52.
Fair Value
-
According to the consensus of 15 analysts, ResMed has 4.26% upside to fair value with a price target of $264.49 per share.
RMD vs. S&P 500
-
Over the past 5 trading days, ResMed has overperformed the S&P 500 by 0.74% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ResMed does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ResMed has grown year-over-year revenues for 16 quarters straight. In the most recent quarter ResMed reported revenues of $1.3B.
Earnings Growth
-
ResMed has grown year-over-year earnings for 5 quarters straight. In the most recent quarter ResMed reported earnings per share of $2.48.
Enterprise value:
36.9B
EV / Invested capital:
5.94x
Price / LTM sales:
7.45x
EV / EBIT:
24.01x
EV / Revenue:
7.36x
PEG ratio (5yr expected):
0.77x
EV / Free cash flow:
23.68x
Price / Operating cash flow:
23.98x
Enterprise value / EBITDA:
21.05x
Gross Profit (TTM):
$3B
Return On Assets:
18.44%
Net Income Margin (TTM):
26.15%
Return On Equity:
25.76%
Return On Invested Capital:
22.47%
Operating Margin:
33%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $4B | $4.6B | $5B | $1.2B | $1.3B | |
| Gross Profit | $2.3B | $2.6B | $3B | $692.8M | $766.4M | |
| Operating Income | $1.1B | $1.3B | $1.6B | $374.6M | $426.3M | |
| EBITDA | $1.3B | $1.5B | $1.8B | $429.2M | $478.2M | |
| Diluted EPS | $5.87 | $6.51 | $8.91 | $2.04 | $2.48 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.5B | $1.7B | $2.3B | $2.4B | $3.2B | |
| Total Assets | $4.6B | $4.9B | $6.7B | $6.8B | $7.6B | |
| Current Liabilities | $876.5M | $667.3M | $761.7M | $773M | $940.5M | |
| Total Liabilities | $1.9B | $1.6B | $2.8B | $2.2B | $2B | |
| Total Equity | $2.7B | $3.3B | $3.9B | $4.6B | $5.5B | |
| Total Debt | $731M | $680.7M | $1.6B | $1B | $673M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $535.3M | $1.2B | $1.7B | $402M | $578.7M | |
| Cash From Investing | -$1.2B | -$269.8M | -$112.8M | -$33.2M | -$31.8M | |
| Cash From Financing | $669M | -$914.6M | -$835.6M | -$335.9M | -$144.1M | |
| Free Cash Flow | $407.7M | $1.1B | $1.6B | $378.9M | $554.9M | |
RMD
Sector
Market Cap
$37.2B
$32.8M
Price % of 52-Week High
96.44%
46.28%
Dividend Yield
0.84%
0%
Shareholder Yield
1.81%
-0.74%
1-Year Price Total Return
18.95%
-35.38%
Beta (5-Year)
0.778
0.632
Dividend yield:
0.84%
Annualized payout:
$1.92
Payout ratio:
23.14%
Growth streak:
3 years
Technicals
8-day SMA
Buy
Level
$251.72
200-day SMA
Buy
Level
$238.14
Bollinger Bands (100)
Buy
Level
221.18 - 248.46
Chaikin Money Flow
Buy
Level
247.5M
20-day SMA
Buy
Level
$249.20
Relative Strength Index (RSI14)
Buy
Level
63.75
ADX Line
Buy
Level
21.96
Williams %R
Sell
Level
-8.6407
50-day SMA
Buy
Level
$240.17
MACD (12, 26)
Buy
Level
3.13
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
295.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.9814)
Buy
CA Score
(Annual)
Level (1.4073)
Buy
Beneish M-Score
(Annual)
Level (-2.4845)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-3.4093)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Stock Forecast FAQ
In the current month, RMD has received 8 Buy ratings 6 Hold ratings, and 1 Sell ratings. The RMD average analyst price target in the past 3 months is $264.49.
-
Where Will ResMed Stock Be In 1 Year?
According to analysts, the consensus estimate is that ResMed share price will rise to $264.49 per share over the next 12 months.
-
What Do Analysts Say About ResMed?
Analysts are divided on their view about ResMed share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ResMed is a Sell and believe this share price will drop from its current level to $200.00.
-
What Is ResMed's Price Target?
The price target for ResMed over the next 1-year time period is forecast to be $264.49 according to 15 Wall Street analysts, 8 of them rate the stock a Buy, 1 rates the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is RMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ResMed is a Buy. 8 of 15 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RMD?
You can purchase shares of ResMed via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ResMed shares.
-
What Is The ResMed Share Price Today?
ResMed was last trading at $254.38 per share. This represents the most recent stock quote for ResMed. Yesterday, ResMed closed at $254.52 per share.
-
How To Buy ResMed Stock Online?
In order to purchase ResMed stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will RocketLab Stock Be In 5 Years?
Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…
Is MO dividend Worth It?
Altria Group (NYSE: MO) is paying investors $1.02 a share…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
88
CDTX alert for Jun 24
Cidara Therapeutics [CDTX] is up 113.42% over the past day.
Sell
46
HIMS alert for Jun 24
Hims & Hers Health [HIMS] is down 34.62% over the past day.
Sell
45
WGS alert for Jun 24
GeneDx Holdings [WGS] is up 18.69% over the past day.
